ClinicalTrials.gg
CompletedNCT04967443Updated Jul 12, 2024Results posted

Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules

A Phase 1 interventional study of Prazosin HCl 2mg and Prazosin HCl 1 mg in Hypertension and Heart Failure, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-12.

Sponsored by Pfizer · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Hypertension by Pfizer — none open to participants now, none under way, none of them phase 3. Hypertension · Pfizer.

Enrollment
8th of 11
72 · median 134
Started
2021
the only one that year
Phase 1
2 of 16
none open now
Registered
16th of 16
by date

Among the 16 studies in Hypertension by Pfizer, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2021, is one of 2 in phase 1, and was the 16th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 16 studies in Hypertension by Pfizer is open now. The open studies under Hypertension, anywhere →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Hypertension by Pfizer as a file.
02

Study summary

Prazosin hydrochloride (HCl) is an oral anti-hypertensive indicated for the treatment of primary and secondary hypertension and heart failure. Pfizer Inc. is the marketing authorization holder for prazosin HCl oral capsules and intended to transfer drug product manufacturing operations from Pfizer, Barceloneta Puerto Rico to Pfizer Pharmaceutical, Ascoli, Italy. To support the manufacturer site transfer and process changes, this bioequivalence (BE) study is being conducted.

This study will be a 2 Cohort, open-label, randomized, single dose study in healthy adult male and/or female participants. Cohort 1 will be crossover with 3 treatments, 3 periods, 6 sequences. Cohort 2 will be crossover with 2 treatments, 2 periods, 2 sequences. Primary objective of this study is demonstrate bioequivalence between prazosin HCl 1, 2 and 5 mg capsules manufactured at Ascoli versus prazosin HCl 2 and 5 mg capsules manufactured at Barceloneta under fasting conditions in healthy adult participants. Approximately 36 participants will be enrolled in each Cohort 1 and Cohort 2.

Pharmacokinetic and statistical analysis will be performed for prazosin. Data from 2 Cohorts will be analyzed separately. The PK parameters area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast), and from time zero extrapolated to infinite time (AUCinf), maximum plasma concentration (Cmax), time to first occurrence of Cmax (Tmax), and terminal phase elimination half-life (t½) will be summarized descriptively by analyte and treatment.

For primary objective, bioequivalence of the Test treatment relative to Reference treatment will be concluded if the 90% confidence intervals (CI) for the ratio of adjusted geometric means of Test treatments relative to Reference treatment for AUCinf (if data permit), AUClast and Cmax, fall wholly within (80%, 125%).

03

Conditions studied

  • Hypertension
  • Heart Failure
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 18 to 55 years of age, inclusive, at the time of signing the Document (ICD).
  • Male and female participants who are overtly healthy as determined by medical evaluation including medical history, full physical examination, vital signs, 12-lead (ECG), and/or clinical laboratory tests.
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations , and other study procedures.
  • (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).
  • Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.
  • Any condition possibly affecting drug absorption (eg, gastrectomy).
  • History of (HIV) infection, , or ; positive testing for HIV, hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb) or hepatitis C antibody (HCVAb). Hepatitis B vaccination is allowed.
  • Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of study intervention.
  • A positive urine drug test.
  • Screening supine blood pressure (BP) ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest.
  • Baseline standard 12 lead that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.
  • Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:
  • (AST) or alanine aminotransferase (ALT) level ≥1.5 × (ULN);
  • Total level ≥1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ≤ ULN.
  • History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.
  • Use of tobacco or nicotine containing products in excess of the equivalent of 5 cigarettes per day. For chewing tobacco, one chew is equivalent to approximately 2 to 3 cigarettes, so participants would be limited to 2 or less chews per day.
  • History of sensitivity to prazosin hydrochloride or any of the components in the formulation of the study products.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Active comparator
    Prazosin Hydrochloride (HCL) 2 milligram (mg) capsule Barceloneta site

    One 2 mg capsule manufactured at the current site, Barceloneta

    Drug: Prazosin HCl 2mg

  • Experimental
    Prazosin HCL 2 mg capsule Ascoli site

    One 2 mg capsule manufactured at the proposed site (Ascoli)

    Drug: Prazosin HCl 2mg

  • Experimental
    Prazosin HCL 1 mg capsule Ascoli site

    Two 1 mg capsule manufactured at the proposed site, Ascoli

    Drug: Prazosin HCl 1 mg

  • Active comparator
    Prazosin HCL 5 mg capsule Barceloneta site

    One 5 mg capsule manufactured at the current site, Barceloneta

    Drug: Prazosin HCl 5 mg

  • Active comparator
    Prazosin HCL 1 x 5 mg capsule Ascoli site

    One 5 mg capsule manufactured at the proposed site, Ascoli

    Drug: Prazosin HCl 5 mg

Interventions

  • Prazosin HCL 1 X 2 mg capsule.

    Also known as: Minipress 2 mg capsule.

  • Prazosin HCl 2 X 1 mg capsule.

    Also known as: Minipress 1 mg capsule.

  • Prazosin HCL 1 X 5 mg capsule.

    Also known as: Minipress 5 mg capsule.

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Prazosin

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of each period

  2. Maximum Observed Plasma Concentration (Cmax) of Prazosin

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of each period

Secondary outcomes

  1. Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Prazosin

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of each period

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Prazosin

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of each period

  3. Plasma Decay Half-Life (t1/2) of Prazosin

    Plasma terminal elimination half-life of Prazosin was measured.

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of each period

  4. Number of Participants With Adverse Events (AEs) According to Seriousness

    Adverse events (AEs): any untoward medical occurrence in a clinical investigation participant administered a product or medical device, without regard to causality. Treatment-emergent AEs (TEAEs): AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). Time frame for safety monitoring was from screening to Follow-Up Completion (Day 35 after the last dose administration of the last period), and the actual time frame might vary according to the number of doses received and the length of washing period of each dose for each participant.

    Time frame: Time frame varied from 20 days to 94 days for cohort 1, and 8 days to 73 days for cohort 2.

07

Results

Posted Jul 12, 2024

Participant flow

Screening
Participant flow — Screening
MilestonePrazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 2x1 mg (Ascoli)Prazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Ascoli)Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 2x1 mg (Ascoli)Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta)Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 1x2 mg (Ascoli)Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta)Prazosin HCL 1x5 mg (Barceloneta) => Prazosin HCL 1x5 mg (Ascoli)Prazosin HCL 1x5 mg (Ascoli) => Prazosin HCL 1x5 mg (Barceloneta)
Started6666661818
Completed6666661818
Not completed00000000
Open Label Treatment
Participant flow — Open Label Treatment
MilestonePrazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 2x1 mg (Ascoli)Prazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Ascoli)Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 2x1 mg (Ascoli)Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta)Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 1x2 mg (Ascoli)Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta)Prazosin HCL 1x5 mg (Barceloneta) => Prazosin HCL 1x5 mg (Ascoli)Prazosin HCL 1x5 mg (Ascoli) => Prazosin HCL 1x5 mg (Barceloneta)
Started6666661818
Completed5555651615
Not completed11110123
Withdrew: Death10000000
Withdrew: Lost to follow-up00100000
Withdrew: Withdrawal by subject01010123
Follow-Up
Participant flow — Follow-Up
MilestonePrazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 2x1 mg (Ascoli)Prazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Ascoli)Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 2x1 mg (Ascoli)Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta)Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 1x2 mg (Ascoli)Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta)Prazosin HCL 1x5 mg (Barceloneta) => Prazosin HCL 1x5 mg (Ascoli)Prazosin HCL 1x5 mg (Ascoli) => Prazosin HCL 1x5 mg (Barceloneta)
Started6666661818
Completed5554651615
Not completed11120123
Withdrew: Death10000000
Withdrew: Lost to follow-up00110000
Withdrew: Withdrawal by subject01010123

Outcome measures

PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Prazosin
Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of each period
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Prazosin
nanogram*hour per milliliter (ng*hr/mL)Prazosin HCL 1x2 mg (Barceloneta)Prazosin HCL 1x2 mg (Ascoli)Prazosin HCL 2x1 mg (Ascoli)Prazosin HCL 1x5 mg (Barceloneta)Prazosin HCL 1x5 mg (Ascoli)
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Prazosin85.77 ± 3488.37 ± 3192.39 ± 34192.3 ± 147252.2 ± 37
Statistical analysis
  • Prazosin HCL 1x2 mg (Ascoli) · Mixed Models Analysis · Ratio of adjusted geometric means: 102.10 · 90% CI 96.14 to 108.43
  • Prazosin HCL 2x1 mg (Ascoli) · Mixed Models Analysis · Ratio of adjusted geometric means: 104.87 · 90% CI 98.68 to 111.44
  • Prazosin HCL 1x5 mg (Barceloneta) vs Prazosin HCL 1x5 mg (Ascoli) · Mixed Models Analysis · Ratio of adjusted geometric means: 104.45 · 90% CI 99.58 to 109.55
PrimaryMaximum Observed Plasma Concentration (Cmax) of Prazosin
Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of each period
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Prazosin
nanogram per milliliter (ng/mL)Prazosin HCL 1x2 mg (Barceloneta)Prazosin HCL 1x2 mg (Ascoli)Prazosin HCL 2x1 mg (Ascoli)Prazosin HCL 1x5 mg (Barceloneta)Prazosin HCL 1x5 mg (Ascoli)
Maximum Observed Plasma Concentration (Cmax) of Prazosin14.82 ± 4917.04 ± 3619.20 ± 3730.91 ± 14338.69 ± 132
Statistical analysis
  • Prazosin HCL 1x2 mg (Ascoli) · Mixed Models Analysis · Ratio of adjusted geometric means: 113.96 · 90% CI 102.79 to 126.34
  • Prazosin HCL 2x1 mg (Ascoli) · Mixed Models Analysis · Ratio of adjusted geometric means: 126.83 · 90% CI 114.32 to 140.70
  • Prazosin HCL 1x5 mg (Barceloneta) vs Prazosin HCL 1x5 mg (Ascoli) · Mixed Models Analysis · Ratio of adjusted geometric means: 118.07 · 90% CI 106.46 to 130.94
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Prazosin
Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of each period
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Prazosin
ng*hr/mLPrazosin HCL 1x2 mg (Barceloneta)Prazosin HCL 1x2 mg (Ascoli)Prazosin HCL 2x1 mg (Ascoli)Prazosin HCL 1x5 mg (Barceloneta)Prazosin HCL 1x5 mg (Ascoli)
Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Prazosin89.10 ± 3390.28 ± 3193.01 ± 31236.7 ± 37259.0 ± 37
Statistical analysis
  • Prazosin HCL 1x2 mg (Ascoli) · Mixed Models Analysis · Ratio of adjusted geometric means: 100.91 · 90% CI 94.92 to 107.27
  • Prazosin HCL 2x1 mg (Ascoli) · Mixed Models Analysis · Ratio of adjusted geometric means: 102.08 · 90% CI 95.97 to 108.57
  • Prazosin HCL 1x5 mg (Barceloneta) vs Prazosin HCL 1x5 mg (Ascoli) · Mixed Models Analysis · Ratio of adjusted geometric means: 104.04 · 90% CI 99.09 to 109.23
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of Prazosin
Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of each period
Reported as:
Median · hr
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Prazosin
hrPrazosin HCL 1x2 mg (Barceloneta)Prazosin HCL 1x2 mg (Ascoli)Prazosin HCL 2x1 mg (Ascoli)Prazosin HCL 1x5 mg (Barceloneta)Prazosin HCL 1x5 mg (Ascoli)
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Prazosin2.00 (0.750 to 6.03)2.00 (0.500 to 4.00)1.50 (0.500 to 3.50)2.50 (1.00 to 8.03)2.00 (0.500 to 8.00)
SecondaryPlasma Decay Half-Life (t1/2) of Prazosin

Plasma terminal elimination half-life of Prazosin was measured.

Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of each period
Reported as:
Mean · hr
Plasma Decay Half-Life (t1/2) of Prazosin
hrPrazosin HCL 1x2 mg (Barceloneta)Prazosin HCL 1x2 mg (Ascoli)Prazosin HCL 2x1 mg (Ascoli)Prazosin HCL 1x5 mg (Barceloneta)Prazosin HCL 1x5 mg (Ascoli)
Plasma Decay Half-Life (t1/2) of Prazosin5.330 ± 1.24945.236 ± 1.05655.022 ± 1.16914.676 ± 1.14224.775 ± 1.1594
SecondaryNumber of Participants With Adverse Events (AEs) According to Seriousness

Adverse events (AEs): any untoward medical occurrence in a clinical investigation participant administered a product or medical device, without regard to causality. Treatment-emergent AEs (TEAEs): AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). Time frame for safety monitoring was from screening to Follow-Up Completion (Day 35 after the last dose administration of the last period), and the actual time frame might vary according to the number of doses received and the length of washing period of each dose for each participant.

Time frame:
Time frame varied from 20 days to 94 days for cohort 1, and 8 days to 73 days for cohort 2.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) According to Seriousness
ParticipantsPrazosin HCL 1x2 mg (Barceloneta)Prazosin HCL 1x2 mg (Ascoli)Prazosin HCL 2x1 mg (Ascoli)Prazosin HCL 1x5 mg (Barceloneta)Prazosin HCL 1x5 mg (Ascoli)
Participants with non-serious AEs (all-causality)10561718
Participants with non-serious AEs (treatment-related)9451618
Participants with SAEs (all-causality)10000
Participants with SAEs (treatment-related)00000

Adverse events

Collected over Time frame for safety monitoring was from screening to Follow-Up Completion (Day 35 after the last dose administration of the last period), and the actual time frame might vary according to the number of doses received and the length of washing period of each dose for each participant. Actual time frame varied from 20 days to 94 days for cohort 1, and 8 days to 73 days for cohort 2.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prazosin HCL 1x2 mg (Barceloneta)1/34 (2.9%)1/34 (2.9%)8/34 (23.5%)
Prazosin HCL 1x2 mg (Ascoli)0/33 (0%)0/33 (0%)4/33 (12.1%)
Prazosin HCL 2x1 mg (Ascoli)0/33 (0%)0/33 (0%)5/33 (15.2%)
Prazosin HCL 1x5 mg (Barceloneta)0/33 (0%)0/33 (0%)16/33 (48.5%)
Prazosin HCL 1x5 mg (Ascoli)0/34 (0%)0/34 (0%)18/34 (52.9%)
Most frequent serious events
Most frequent serious events
EventPrazosin HCL 1x2 mg (Barceloneta)Prazosin HCL 1x2 mg (Ascoli)Prazosin HCL 2x1 mg (Ascoli)Prazosin HCL 1x5 mg (Barceloneta)Prazosin HCL 1x5 mg (Ascoli)
Road traffic accidentInjury, poisoning and procedural complications1/340/330/330/330/34
Most frequent other events
Most frequent other events
EventPrazosin HCL 1x2 mg (Barceloneta)Prazosin HCL 1x2 mg (Ascoli)Prazosin HCL 2x1 mg (Ascoli)Prazosin HCL 1x5 mg (Barceloneta)Prazosin HCL 1x5 mg (Ascoli)
DizzinessNervous system disorders0/340/330/339/337/34
NauseaGastrointestinal disorders2/341/331/337/339/34
HeadacheNervous system disorders2/342/332/333/335/34
Orthostatic hypotensionVascular disorders4/341/332/333/332/34
TachycardiaCardiac disorders0/340/330/331/334/34
SomnolenceNervous system disorders0/340/330/330/332/34

Baseline characteristics

Age, Customized
Age, Customized(Participants)Cohort 1: MaleCohort 1: FemaleCohort 2: MaleCohort 2: FemaleTotal
<18 years00000
18-44 years167181051
45-64 years852621
≥65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: MaleCohort 1: FemaleCohort 2: MaleCohort 2: FemaleTotal
Female01201628
Male24020044
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: MaleCohort 1: FemaleCohort 2: MaleCohort 2: FemaleTotal
Hispanic or Latino1148932
Not Hispanic or Latino13812740
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: MaleCohort 1: FemaleCohort 2: MaleCohort 2: FemaleTotal
American Indian or Alaska Native00000
Asian02204
Native Hawaiian or Other Pacific Islander01001
Black or African American815418
White168131249
More than one race00000
Unknown or Not Reported00000
08

Study locations

1 site
  • Clinical Trials of Texas, LLC
    San Antonio, Texas 78229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Feb 2022, 4 months.

Results were first posted in Jul 2024, 2 years 4 months after primary completion.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 4 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2021
First posted
Jul 19, 2021
StartActual
Sep 22, 2021
Primary completionActual
Feb 15, 2022
CompletionActual
Feb 15, 2022
Results first posted
Jul 12, 2024
Last update
Jul 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04967443
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 19, 2021
Start date
Sep 22, 2021
Primary completion
Feb 15, 2022
Completion
Feb 15, 2022
Results posted
Jul 12, 2024
Last update
Jul 12, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prazosin

Start the discussion